GlassScriptPhysician profile
Kenneth M Eugene
NPI 1801950530
$2,679.97
in general payments reported to CMS, 2019-2025
27 companies · $484 in 2025
The $484 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $374 · 2020: $493 · 2021: $207 · 2022: $177 · 2023: $526 · 2024: $419 · 2025: $484.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,429.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,428.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $555.24 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Novo Nordisk INC | $470.65 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $320.40 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $271.05 | 2019-2025 | Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $179.01 | 2019-2025 | Jardiance |
| Amgen INC. | $164.06 | 2020-2025 | Repatha, Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $106.33 | 2019-2023 | |
| Exact Sciences Corporation | $69.67 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $62.38 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $58.91 | 2025 | Gemtesa |
| Allergan, INC. | $52.78 | 2019-2020 | |
| Abbott Laboratories | $51.30 | 2022-2023 | Freestyle Libre 3 |
| Dexcom, INC. | $50.95 | 2024-2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $36.67 | 2024-2025 | Trelegy Ellipta |
| Esperion Therapeutics, INC. | $30.09 | 2022-2024 | Nexletol |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $27.59 | 2020-2021 | |
| Boston Scientific Corporation | $25.22 | 2025 | General - Pain Management |
| Astellas Pharma US INC | $22.70 | 2024 | Veozah |
| Abiomed | $16.13 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $16.00 | 2023 | Livalo, Seglentis |
| Ibsa Pharma INC. | $15.70 | 2023 | Tirosint, Licart |
| Pbg Puerto Rico LLC | $15.64 | 2021 | |
| Merck Sharp & Dohme LLC | $13.91 | 2020 | |
| Arbor Pharmaceuticals, INC. | $12.31 | 2019 | |
| Abbvie INC. | $11.85 | 2022 | |
| Daiichi Sankyo INC. | $11.74 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.69 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Eugene listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.